China's new drug industry is warned by the Securities and Regulatory Bureau to disclose financial data

23rd evening, the New drug industry (market, interrogation) announced that the company on September 22, 2013 received a letter from the Tianjin Securities and Regulatory Bureau issued a letter, because the company in advance on the company's website disclosure of financial data, violated the provisions of the envelope. Financial profit Po, the current savings rate increase 1000% announcement, the Chinese new drug industry on July 18, on its website disclosed the first half of the financial data, and the company on August 15 only in the CSRC designated media disclosure of the 2013.5 Annual report, which violates the "Listed Companies Information disclosure management measures" provisions, namely "Information disclosure obligation person in the company's Web site and other media to publish information not prior to the designated media."